We evaluated a new commercially available two-site immunoradiometnc assay (IRMA; BioM#{233}rieux '251-EPO C0atRIA) for erythropoietin (EPO) in human serum. The precision (CV) was 4.1% intra-assay and 8% interassay for a serum pool with an EPO concentration of 17 mt. units/L; the detection limit was 0.5 mt. unit/L, one order of magnitude lower than by classical radioimmunoassay (RIA), although standardization of IRMA and AlA were similar. Results by both IRMAand RIA are compared for normal subjects, patients with nonrenal nonmnflammatory anemias, patients with p-thalassemia major, hemodialysis patients, and patients with primary or secondary polycythemia. Values by IRMA compared well with those by AlA in the upper area of the range; IRMAand RIA values for EPO show parallel expected variations with the degree of anemia. However, because of its greater sensitivity and specificity, we consider the IRMA more appropriate than RIA for investigating patients with sub-normal EPO concentrations.
treated with EPO (Hb: 53 to 123 g/L);9 hypoxemic patients with chronic obstructive pulmonary disease and secondary polycythemia (p02. mmHg Jib, 155-175 g/L; hematocrit, 47-66%); and 7 patients with untreated polycythemia vera (po2 >70 mmHg, Jib 170 200 g/L, hematocrit 53-61%). No anticoagulant was added. Thalassemic patients were investigated on at least five occasions to cover a complete transfusion cycle: before transfusion (time n), immediately after the end of this transfusion, 5-14 days later (median: 9 days), and before and after transfusion (time n + 1). For other anemic patients, care was taken to exclude those who had a recent transfusion. Healthy subjects working in the laboratory, 13 men and 13 women, ages 26 to 53 years, served as controls. Informed consent was obtained from all subjects.
Serum Pools
Pooled specimens of human serum were used to determine assay performance. These were a low-concentration pool (sera from normal subjects and patients with chronic renal failure), a medium-concentration pool (sera from patients with mild nonrenal anemia), and a high-concentration pooi (sera from patients with nonrenal severe anemia).
Procedures

IRMA. The assay I-EPO
CoatRIA (supplied by BioM#{233}rieux, Marcy-LEtoile, Lyon, France) includes two monoclonal anti-EPO antibodies (mouse) raised against human recombinant EPO. As described previously (5) , these antibodies bind with two different epitopes of the peptide sequence, both involved in the interaction of EPO with its receptor. Their binding is independent of the presence of the sugars, One antibody, Ad, is fixed on the test tube, while the other, Ac2, is labeled with 'I.
Standards of urinary EPO were prepared in HC1 (100 mmol/L, pH 7.3) containing bovine serum albumin (Cohn Fthction V), 50 gIL, and merthiolate, 0.1 g/L. The assay was calibrated against the Second MRC Reference Preparation 67/343 (urine EPO; National Institute for Biological Standards and Control, Potters Bar, U.K.).
A one-step procedure was used, with EPO and Ac2 added simultaneously to the coated tube. After a 3-h incubation at room temperature, with constant mixing, the tube was washed and its radioactivity was counted. EPO that had bound both Ad and I-labeled Ac2 was measured. 
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IRMA. Figure l#{192} shows the entire standard curve and unitlL. All dilutions were done with the zero standard.
The results obtained with these low concentrations were linearly distributed. The precision was evaluated by repeated testing of the three pools (10 times intra-assay; 9 times interassay). The intra-assay and interassay coefficients of variation (Table 3) 
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Recovsry, O.517x-2.34, r2= 0.948, S,,,,= 1.14(n = 9);(F)y= -0.21x+ 0.3(6, r= 0.104, S,, down to this lower detection limit (Figure 5) sensitivity, which allows one to explore EPO concentra-' tion in the normal and subnormal ranges.
